98 development "https:" "https:" "https:" "Univ" positions at UNIVERSITY OF SOUTHAMPTON
Sort by
Refine Your Search
-
Listed
-
Category
-
Country
-
Field
-
in health & safety management and performance is critical to the continuing and developing success of our exceptional institution. We require a Radiation Protection / Health and Safety Officer to join
-
human models as part of a Medical Research Council – Developmental Pathway Funding Scheme (MRC-DPFS) grant in 2023 in collaboration with Professor Jonathan K Watts from the RNA Therapeutics Institute
-
Innovation is the lifeblood of the University of Southampton. Powered by world-class research, we enable spin-out companies across the country, enabling the development of products and services
-
. This initiative, developed in response to India's New Education Policy, represents a significant investment in transnational education. The campus provides Indian students with the opportunity to earn a globally
-
effectively across disciplines, and well-developed organisational skills. In this role, your primary focus will be the characterisation and understanding of TMDC-based nanoelectronic devices, such as
-
, and (4) co-produce recommendations with disabled people to make politics more accessible. The post holder will take a prominent role in developing the conceptual and methodological innovations to study
-
addition to the essential disciplinary research skills, candidates should demonstrate a genuine enthusiasm for collaborative working, the ability to communicate effectively across disciplines, and well-developed
-
of Southampton. We are seeking a collaborative and motivated postdoctoral scientist to work on our Blood Cancer UK-funded programme developing next-generation, off-the-shelf immunotherapies for acute myeloid
-
components for innovative-lasers applications. We’re looking for an enthusiastic postdoctoral fellow to be part of our team to advance our Rapid Pulsed Laser Deposition (RPLD) technology and ultimately develop
-
postdoctoral scientist to work on our Blood Cancer UK-funded programme developing next-generation, off-the-shelf immunotherapies for acute myeloid leukaemia (AML). This three-year project will harness cytotoxic